Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy

Obinutuzumab treatment is extremely effective and safe in patients with MN and rituximab-resistant NS and can achieve persistent remission in this population.

Institutions

Publication Details

Journal
Kidney International Reports
Published
2025-12-19
DOI
https://doi.org/10.1016/j.ekir.2025.103728
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy

Kidney International Reports
Renal Diseases and Glomerulopathies
article

Prospective Cohort Study of Obinutuzumab in Rituximab-Resistant Primary Membranous Nephropathy

article en

Abstract

Obinutuzumab treatment is extremely effective and safe in patients with MN and rituximab-resistant NS and can achieve persistent remission in this population.

Kidney International ReportsVol. 11(3)
Mario Negri Institute for Pharmacological Research (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Ospedale Papa Giovanni XXIII (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT)
European Rare Kidney Disease Reference Network
Zero hunger
Openalex Percentile: Top 33%
Renal Diseases and Glomerulopathies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.